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Summary.-Administration of C. parvum alone did not improve the survival of
C57BL/6 mice injected with the EL4 lymphoma. The anti-tumour effect of anti-EL4
Ig was however increased by C. parvum treatment, and the combination therapy of
anti-EL4 Ig and cytotoxic drugs was even more improved. However, C. parvum only
had this effect when given by the same i.p. route as the tumour cells, and the effect
was greater when C. parvum was injected 5 days before than 1 day after tumour cells.
DURING THE PAST TWO DECADES, there
has been a resurgence ofinterest in the use
of immunotherapeutic measures in the
treatment of tumours (Oettgen, 1977;
Salmon, 1977). The greater part of this
interest has been directed towards active
immunotherapy aimed at stimulating a
response in the individual against his own
tumour, but in addition there has been a
considerable amount of work on the use
of tumour-directed antibodies as a passive
form oftherapy. This work has shown that
in a range of animal tumours, passively
administered tumour-specific or tumour-
directed antibodies can inhibit tumour
growth. The effect, however, is generally
modest, especially against established
tumours (see Rosenberg & Terry, 1977)
although it can at times be extended by
the concomitant use of cytotoxic drugs
(Davies et al., 1974; Rubens et al., 1975;
Reif et al., 1977). This limitation might be
a reflection of inadequate levels of anti-
bodies used in the experiments. However,
it is possible that the restricted effective-
ness is due to some other limiting factor
which cannot be circumvented by simply
increasing the dose of Ig. Although the
detailed mechanism by which antibodies
inhibit tumour progression is not under-
stood, it is reasonable to conjecture that
it involves some cooperation with the
immune or mononuclear phagocytic sys-
tems, and that measures which stimulate
either or both of these might increase the
effectiveness of passive antibody treat-
ment. We report here the results ofa series
of experiments which explored some as-
pects of this question, using the EL4
lymphoma of C57BL/6 mice. We are
aware of the implications of immuno-
logical heterogeneity for specific immuno-
therapy (Kerbel, 1979) and that progres-
sive growth of a long-established tumour
such as EL4 is unlikely to involve this
phenomenon. It nevertheless seemed valid
to test the hypothesis in this system, in
which limited effectiveness of passively
adtninistered antibody has already been
shown.
MATERIALS AND METHODS
Mice.-Inbred C57BL/6 mice, about 10
weeks old, from our own SPF colony were
used throughout.
Tumour.-The EL4 lymphoma was main-
tained as an ascites. For experiments, it was
injected by the route indicated at a dose of
5 x 104 viable cells per mouse.
Anti-EL4 globulin.-Anti-EL4 serum was
raised in rabbits by 3 s.c. injections of 108
live EL4 cells at 10-day intervals. No adju-G. J. (YNEILL AND N. STEBBING
vant was used. The animals were bled out 10
days after the third injection, the serum
recovered and heat-inactivated at 56°C for
30 min. The globulin fraction was recovered
by precipitation with 40%o ammonium sul-
phate. Anti-EL4 serum raised in this way is
non-toxic, and can be used without absorp-
tion. The antiserum against Lewis lung car-
cinoma was a pool from 6 rabbits given 3
s.c. injections of0 5-0 75 ml oftumour homo-
genate at 10-day intervals. Two of the
rabbits were given the tumour as an emulsion
in complete Freund's adjuvant. The rabbits
were bled 10 days after the third injection,
the serum recovered and heat-inactivated,
and unfractionated. (This antiserum was pre-
pared by P. D. E. Jones.)
C. parvum. C. parvuan (Lot CA749) was
obtained from Burroughs Welleome Ltd. In
one experiment, a strain of C. parvum (CN
5888) which lacks lymphoreticular stimu-
latory properties was also used (Adlam &
Scott, 1973). Both strains were used at a level
of 0 47 mg per mouse. Cytosine arabinoside
(Ara-C, Sigma), cyclophosphamide (Endox-
ana, Ward Blenkinsop), vineristine (Oncovin,
E. Lilly) and adriamycin (Farmitalia) were
used as solutions in 0.900 saline. Mice were
treated on three successive days beginning
48 h after injection of tumour cells (24 h in
the case of the experiment shown in Table
VII). Each treatment was at the dose stated
in the tables. When both Ig and a drug were
being used, the drug was injected about 1 h
before the Ig.
Muramyl dipeptide (MDP) was obtained
from Institut Pasteur Production, and w%as
used as a solution in 0.9%o saline.
Statistics.-The survival time of mice was
obtained from records prepared daily for at
least 50 days after tumour inoculation. A
measure of the average survival time for a
group of mice, which takes account of sir-
viving animals, was obtained by calculating
the reciprocal of the mean of the reciprocals
of the survival times of individuals. These
harmonic means (x, in days) which have been
found to agree with rank-order means (Steb-
bing, 1977) are used throughout. Significant
differences in survival times of different
groups were tested for by calculating logrank
x2 values as described by Peto & Pike (1973).
Significance levels are indicated by P for
comparisons made with untreated control
groups, and P1 comparisons between C.
parvrum and no C. parvum.
RESULTS
Injection of C. parvrum (i.p.) 5 days
before i.p. injection of EL4 cells did not,
on its own, influence survival, as shown
by the data in Table I. In this experiment,
cytosine arabinoside (Ara-C) at a dose of
1 mg caused a small but significant
increase in survival time, and 1 mg of
anti-EL4 Ig was ineffective. However, the
combination of the drug and the anti-EL4
was more protective than either agent
alone, as has been previously found
(Davies & O'Neill, 1973; Davies, 1974).
Pre-treatment of mice with C. parvum
significantly increased the mean survival
time of mice treated with anti-EL4 Ig or
Ara-C plus anti-EL4 Ig.
This improvement in the efficacy of
anti-EL4 Ig could not be obtained by
using it in larger amounts, as is evident
from the results of a further experiment
shown in Table II. Without C. parvum
pre-treatment, anti-EL4 Ig at doses of
1, 2-5 and 5 mg produced essentially the
same modest but significant increase in
survival time. However, the survival times
were progressively increased in the groups
which had also been pre-treated with
C. parvrum. In contrast, it should be noted
that the effectiveness of different doses of
Ara-C was not influenced by pre-treatment
with C. parvum. C. parvrum was found to
be less effective when given after tumour-
cell injection. Table III gives the results
of 2 experiments in which 24 h elapsed
between injection of EL4 cells and injec-
tion of C. parvum. In Experiment 1, C.
parvum had no effect. In Experiment 2,
it did significantly increase the effective-
ness of anti-EL4 Ig (with and without
Ara-C) but to a much smaller extent than
in those groups in this experinment which
had been pre-treated with C. parvum 5
days before tumour-cell injection (results
not shown).
In the experiments described so far,
the C. parvum and the tumour cells were
injected by the same route (i.p.). In a
further experiment, we compared the
effectiveness of C. parvum given i.p.
against EL4 cells injected s.c. or i.p. The
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TABLE I.-Effect ofC. parvum given i.p. on Day - 5 on survival ofmice injected i.p. with
EL4 and subsequently treated i.p. with anti-EL4 Ig (1 mg) and/or Ara-C (1 my)
+ C. parvum
-r
P x
12-3
<005 17-7
N.S. 19-4
< 0 001 34-3
N
0/5
0/5
0/5
3/10
p P1
N.S.
< 0-05 N.S.
<005 <005
< 0-001 < 0-01
x=Harmonic mean survival time in days.
N=Mice surviving beyond 50 days.
TABLE II.-Effect of C. parvum given i.p. on Day -5 on survival of mice injected i.p.
with EL4 and subsequently treated i.p. with different doses of anti-EL4 Ig or Ara-C
- C. parvum + C. parvum
Treatment A,-A __A_,_-_-A
(mg) x N P x N P
Saline 14-7 0/10 - 141 0/10
Ig 1 16-9 0/10 <0-01 17-9 0/10 <0-01
2-5 18-5 0/10 < 0 01 20-0 0/10 < 0*001
5 17-5 0/10 < 0 05 32-3 3/10 < 0*001
Ara-C 1 19-6 0/10 <0 01 19-6 0/10 <0 001
2-5 21-7 0/10 <00l 21-3 0/10 < 0*001
5 24-4 0/10 < 0 01 22-7 0/10 < 0 001
P1
N.S.
N.S.
N.S.
< 0-001
N.S.
N.S.
N.S.
x =Harmonic mean survival time in days.
N=Mice surviving beyond 50 days.
TABLE III.-Effect of C. parvum given i.p. Day + 1 after injection of EL4 cells (i.p.) on
survival of mice subsequently treated with anti-EL4 Ig (1mg) and/or Ara-C (1 my)
- C. parvum + C. parvum
Treatment
Exp. 1 Saline
Ara-C
Ig
Ara-C+Ig
Exp. 2 Saline
Ara-C
Ig
Ara-C+Ig
N P x N P
11-9 0/5 11-4 0/5
17-0 0/5 < 0.05 16-0 0/5 < 0.05
12-8 0/5 N.S. 14-0 0/5 < 0 05
20-4 0/10 < 0 001 20-0 0/5 < 0.05
13-8 0/10 14-5 0/10 -
19-3 0/10 < 0*01 19 9 0/10 < 0 001
15-1 0/10 < 0 05 18-5 0/10 < 0 01
22-8 0/10 < 0 01 30 5 1/10 < 0 001
k=Harmonic mean survival time in days.
N =Mice surviving beyond 50 days.
results, shown in Table IV, confirm that
C. parvum injected i.p. 5 days before i.p.
tumour challenge substantially improves
the effect of anti-EL4 Ig, and to an even
greater extent the effect of combined anti-
E14 Ig and Ara-C treatment, with 7/10
survivors in this group (in this experiment
there was a modest increase in the effect
of Ara-C alone). However, i.p. C. parvum
did not enhance the effect of anti-EL4 Ig
against s.c. injected EL4 cells. Results in
the first part of Table IV also show that a
rabbit antiserum against the Lewis lung
carcinoma was ineffective against EL4
with or without pretreatment with C.
parvum, indicating that the anti-tumour
effect of C. parvum observed here is de-
pendent on the presence of specific anti-
EL4, antibodies.
The importance of the route of C.
parvum administration relative to the
route of tumour inoculation was explored
further, by comparing the effect of
C. parvumgiven by different routes against
- C. parvum
x N Treatment
Saline
Ara-C
Ig
Ara-C+Ig
12-3
16-2
14-5
19-5
0/5
0/5
0/5
0/10
P1
N.S.
N.S.
N.S.
N.S.
N.S.
N.S.
<0-01
<0-001
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TABLE IV.-Effect of C. parvum given i.p. on Day -5 on survival of mice injected i.p.
or s.c. with 5 X 104 EL4 cells and subsequently treated i.p. with anti-EL4 Ig (1 my)
and/or Ara-C (1 my)
EL4 route Treatment
I.p. Saline
Ara-C
Ig
Ara-C+Ig
Anti-Lewis*
Ara-C +Anti Lewis*
S.c. Saline
Ara-C
Ig
Ara-C+Ig
* 0-25 ml antiserum against Lewis lung carcinoma.
=Harmonic mean survival time in days.
N=Mice surviving beyond 50 days.
TABLE V.-Effect of C. parvum given i.p. or i.v. on Day -5 on survival of mice injected
with EL4 cells i.p. and subsequently treated i.p. with anti-EL4 Ig (1 mg) and/or Ara-C
(1 mg)
+ C. parvum
l.p.
- C. parvum,
x x ~~P1
12 5 12*4 N.S.
17*4 196 <005
14*2 17*3 N.S.
21*3 2380 <0.001
11 4
17*3
11*6
24 2
i.v.
_j A
P1
N.S.
N.S.
< 0*05
N.S.
"Inactive"
C. parvum
i.p.
X P1
12 5 N.S.
17 7 N.S.
14*7 N.S.
212 N.S.
x =Harmonic mean survival time in days.
i.p. injected tumour cells (Table V). In
this experiment, i.p. administration of
C. parvum produced only a modest in-
crease in the effect of anti-EL4 Ig, but it
substantially increased the survival of
animals treated with both anti-EL4 Ig
and Ara-C, with 5/10 survivors. J.v.
injected C. parvum actually reversed the
effectiveness of anti-EL4 Ig, as can be
seen from the mean survival times in
Table V. This experiment also shows that
the "inactive" strain of C. parvum given
i.p. does not boost the effectiveness of
anti-EL4 Ig. This failure of i.v. injected
C. parvum to augment the effect of anti-
EL4 Ig (with or without Ara-C) does not
seem to be due to the treatment regime
adopted in the above experiment. The
results in Table VI show that when
C. parvum was given i.v. at different
times relative to EL4 injection, the only
significant effects were reductions in mean
survival times. This appeared to be inde-
pendent of the timing with anti-EL4, but
it should be noted that at - 10 days i.v.
C. parvum enhanced tumour growth and
(presumably as aresultofthis)significantly
reduced the effect of Ara-C. The greatest
increase in survival time in this experi-
ment was in the group which had i.v.
C. parvum on Day -1, and subsequent
treatment with both anti-EL4 Ig and
Ara-C. There were 3/10 survivors in this
group, but the mean survival time was not
significantly different from the controls.
Whether or not this combination of C.
parvum, anti-EL4 and drug is capable of
conferring an anti-tumour effect requires
further investigation.
The synthetic adjuvant muramyl
- C. parvum
xR N
+ C. parvum
N
x N
13-1
17-3
13-2
20-0
12-7
16-8
18-5
21-4
19-5
24-4
0/10
0/10
0/10
0/10
0/10
0/10
0/10
0/10
0/10
0/10
13-2
19-1
18-2
87-3
12-7
19-2
17*7
21-5
19-9
27-4
0/10
0/10
0/10
7/10
0/10
0/10
0/10
0/10
0/10
1/10
P1
N.S.
<0-01
<0*001
< 0*001
N.S.
N.S.
N.S.
N.S.
N.S.
N.S.
Treatment
Saline
Ara-C
Ig
Ara-C+Ig
246C. PARVUM IN COMBINATION THERAPY
TABLE VI.-Effect of C. parvum given i.v. at different times relative to i.p. injection of
EL4 cells, on survival of mice subsequently treated with anti-EL4 Ig (1 mg) and/or
Ara-C (1 mg)
Treatment
I A - A
Day of
i.v.
C. parvum
-10
-5
-1
+1
Saline
x P1
14-7
12-2
13-7
13-5
13-9
<0-01
N.S.
N.S.
N.S.
Ig
r A
x Pi
18-2
15-2
15-2
16-1
16-4
<0-05
<005
N.S.
<005
Ara-C
x Pi
18-9
16-4
18-9
18-5
18-5
< 0-01
N.S.
N.S.
N.S.
Ara-C+Ig
xi Pi
25-6
21-3
27-8
37*0
27-8
<0-01
N.S.
N.S.
N.S.
x=Harmonic mean survival time in days.
TABLE VIJ.-Effect of C. parvum given i.p. on Day -5 on survival of mice injected i.p.
with EL4 cells and subsequently treated with anti-EL4 Ig (1 ma) and/or adriamycin
(10 ag), cyclophosphamide (0 5 mg), vincristine (5 ,ua) or cytosine arabinoside (1 ma)
- C. parvum
Treatment x N P
Saline
Ig
Adr.
Adr. +Ig
Cy.
Cy. +Ig
Vincr.
Vincr. +Ig
Ara-C
Ara-C+Ig
13-2
16-9
16-7
28-2
14-9
24-5
17-2
22-0
19-2
29-2
0/10
0/10
0/10
2/10
0/10
1/10
0/10
0/10
0/10
2/10
<0-01
<0-01
< 0-001
N.S.
< 0-001
< 0-01
< 0-001
<0-001
< 0-001
x =Harmonic mean survival time in days.
N=Mice surviving beyond 50 days.
dipeptide (MDP) (Lowy et al., 1977) was
compared with C. parvum in one experi-
ment but, at a dose of 48 ,ug on Day -5,
Day -1 or Day + 1, i.p. injection of
MDP did not influence survival in the
control group or in the groups treated
suibsequently with anti-EL4 Ig and/or
Ara-C (results not shown).
It is clear that in circumstances in which
C. parvum improves the effectiveness of
anti-EL4 Ig, it also increases the effect
ofthe combination ofIg and Ara-C. It was
of interest therefore to find out whether
other drugs showed a similar interaction,
and Table VII gives the result of a com-
parison of adriamycin, cyclophosphamide,
vincristine and cytosine Ara-C. With
cyclophosphamide and vincristine, the
results were unambiguous. The effective-
ness of these drugs on their own was not
influenced by prior administration of C.
parvum, but the combination with anti-
EL4 showed a substantial and significant
improvement in both cases. The combina-
tion of adriamycin and anti-EL4 Ig with-
out C. parvum produced 2/10 survivors,
and this increased to 6/10 in the group
pre-treated with C. parvum, though the
improvement was not statistically sig-
nificant. Whether or not C. parvum can
cause a genuine improvement in the effec-
tiveness of anti-EL4 Ig plus adriamycin
requires further investigation, involving
different doses of the drug.
The survivorsfrom this experiment were
re-challenged with EL4 53 days after the
first tumour-cell injection. There was no
sign of increased resistance, the animals
dying at the same time as previously
unexposed controls.
+ C. parvum
xR N P P1
13-7
24-0
20-6
60-5
15-8
55-1
17-2
63-1
24-2
0/10
1/10
2/10
6/10
0/10
6/10
0/10
6/10
2/10
10/10
< 0-001
< 0-01
<0-001
< 0-01
< 0-01
<0-01
<0-001
< 0-001
< 0-001
N.S.
< 0-001
N.S.
N.S.
N.S.
<0-05
N.S.
< 0-01
N.S.
<0-001
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DISCUSSION
The results presented in this paper show
clearly that under certain experimental
conditions injection of C. parvum in-
creases the effectiveness of anti-tumour
globulin in inhibiting the growth of the
EL4 lymphoma in C57BL/6 mice. This C.
parvum effect can be even more pro-
nounced when the C. parvum is used in
combination with anti-tumour drugs, and
it should be noted that the drugs used
represented groups with different mechan-
isms of action. C. parvum alone did not
inhibit EL4 growth, and its ability to
improve the effectiveness of anti-EL4
(with or without drug) was only clearly
shown when both C. parvum and tumour
cells were injected i.p. When C. parvum
was injected i.p. it failed to influence the
effectiveness of anti-EL4 Ig against s.c.
injected tumour cells. Iv. injected C.
parvum not only failed to increase the
effectiveness of anti-EL4 Ig, but partially
reversed it and, when given 10 days before
i.p. injection of tumour cells, caused
significant enhancement of tumour
growth. This pattern of effectiveness, in
which C. parvum has to be administered
to the site oftumourgrowth, is reminiscent
ofits reported greater effectiveness against
some tumours when given by intra-tumour
injection (see Milas & Scott, 1978). It
should, however, be noted that the treat-
ment adopted in our experiments did not
leave survivors with increased resistance
to re-challenge with EL4 cells, as has been
found by others after intra-lesional injec-
tion of C. parvum (e.g. Likhite & Halpern,
1974). It would be ofinterest to determine
whether administration of C. parvum into
the site of an s.c. EL4 tumour affects the
anti-tumour activity of subsequent treat-
ment with anti-EL4 Ig.
Previously reported anti-tumour effects
of C. parvum have been attributed to
activation of macrophages (Milas & Scott,
1978) and it seems likely that the ability
of C. parvum to increase the effectiveness
of anti-tumour globulin also involves
macrophage activation (it has been re-
ported (Fakhri & Hobbs, 1973) that trans-
fer of normal mouse peritoneal macro-
phages can improve the effectiveness of
tumour-directed antibodies). The detailed
mechanism can only be a matter for
speculation at present. The simplest
explanation might be thatlocallyactivated
macrophages are capable of killing anti-
body-sensitized tumour cells. It is, how-
ever, possible that stimulated production
of some components of complement
(Schorlemmer et al., 1977) might permit a
more effective complement-mediated lysis
ofthe tumour cells (an attempt to improve
the effectiveness of anti-EL4 Ig by trans-
fer of fresh C57BL/6 serum as a source of
complement was, however, unsuccessful-
unpublished results). It should perhaps be
emphasized that in these experiments C.
parvum alone was ineffective, and that the
effect which it augmented was due to the
presence of anti-EL4 antibodies. C. par-
vum may therefore be acting by a mechan-
ism which is different from that by which
it normally inhibits tumour growth.
The role of the cytotoxic drugs in this
system is also unclear. It is known that
combined treatment with C. parvum and
cytotoxic drugs can be beneficial (Hou-
chens et al., 1976) although the timing of
the treatments may be critical (Currie &
Bagshawe, 1970). Our results do not pro-
vide much encouragement for this
approach, but do suggest that the apparent
synergism between tumour-directed anti-
bodies and a range of cytotoxic drugs
(Davies & O'Neill, 1973; Davies, 1974) may
be further improved by the use ofan agent
such as C. parvum. Clearly it is important
to determine whether these effects can be
demonstrated under conditions more
closely related to clinical situations, and
with tumour systems other than the EL4
model used in the present experiments.
WVe are grateful for the expert technical assistance
of Mrs S. Buckham.
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